Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

670 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Effect of an induction period of pegylated interferon-α2a and ribavirin on early virological response in HIV-HCV-coinfected patients: results from the CORAL-2 study.
Tural C, Solà R, Alvarez NP, Moltó J, Sánchez M, Zamora AM, Ornelas A, Laguno M, González J, von Wichmann MÁ, Téllez MJ, Paredes R, Clotet B; CORAL-2 study group. Tural C, et al. Among authors: sola r. Antivir Ther. 2011;16(6):833-41. doi: 10.3851/IMP1837. Antivir Ther. 2011. PMID: 21900715 Clinical Trial.
A multidisciplinary support programme increases the efficiency of pegylated interferon alfa-2a and ribavirin in hepatitis C.
Carrión JA, Gonzalez-Colominas E, García-Retortillo M, Cañete N, Cirera I, Coll S, Giménez MD, Márquez C, Martin-Escudero V, Castellví P, Navinés R, Castaño JR, Galeras JA, Salas E, Bory F, Martín-Santos R, Solà R. Carrión JA, et al. Among authors: sola r. J Hepatol. 2013 Nov;59(5):926-33. doi: 10.1016/j.jhep.2013.06.019. Epub 2013 Jun 26. J Hepatol. 2013. PMID: 23811030 Clinical Trial.
Drug-drug interactions of telaprevir and boceprevir in HCV-monoinfected and HIV/HCV-coinfected patients can modify the adherence.
González-Colominas E, Broquetas T, Retamero A, García-Retortillo M, Cañete N, Coll S, Pellicer R, Giménez MD, Cabrero B, Bory F, Knobel H, Salas E, Solà R, Carrión JA. González-Colominas E, et al. Among authors: sola r. Liver Int. 2015 May;35(5):1557-65. doi: 10.1111/liv.12729. Epub 2014 Dec 15. Liver Int. 2015. PMID: 25385188
Short communication. Baseline factors associated with haematological toxicity that leads to a dosage reduction of pegylated interferon-alpha2a and ribavirin in HIV- and HCV-coinfected patients on HCV antiviral therapy.
Fuster D, Huertas JA, Gómez G, Solà R, González García J, Vilaró J, Pedrol E, Force L, Tor J, Sirera G, Videla S, Planas R, Clotet B, Tural C; PEG-TOX Research Group. Fuster D, et al. Among authors: sola r. Antivir Ther. 2005;10(7):841-7. Antivir Ther. 2005. PMID: 16312180 Clinical Trial.
Prophylactic treatment with escitalopram of pegylated interferon alfa-2a-induced depression in hepatitis C: a 12-week, randomized, double-blind, placebo-controlled trial.
Diez-Quevedo C, Masnou H, Planas R, Castellví P, Giménez D, Morillas RM, Martín-Santos R, Navinés R, Solà R, Giner P, Ardèvol M, Costa J, Diago M, Pretel J. Diez-Quevedo C, et al. Among authors: sola r. J Clin Psychiatry. 2011 Apr;72(4):522-8. doi: 10.4088/JCP.09m05282blu. Epub 2010 Oct 5. J Clin Psychiatry. 2011. PMID: 21034680 Clinical Trial.
Prediction of week 4 virological response in hepatitis C for making decision on triple therapy: the Optim study.
Romero-Gómez M, Turnes J, Ampuero J, Oyagüez I, Cuenca B, Gonzalez-Garcia J, Muñoz-Molina B, Aguilar R, Leal S, Planas R, Garcia-Samaniego J, Diago M, Crespo J, Calleja JL, Casado MA, Sola R. Romero-Gómez M, et al. Among authors: sola r. PLoS One. 2015 Mar 31;10(3):e0122613. doi: 10.1371/journal.pone.0122613. eCollection 2015. PLoS One. 2015. PMID: 25826755 Free PMC article.
670 results